Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Duolingo Inc (DUOL) vs TransMedics Group Inc (TMDX) Price & Performance

Duolingo IncTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Duolingo Inc vs TransMedics Group Inc — how do they compare? Duolingo Inc trades at $133.19 (market cap $6.34B), while TransMedics Group Inc trades at $87.13 (market cap $3.10B). The key difference: Duolingo Inc is far larger — about 2× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals.

DUOLTMDX
Market Cap
$6.34B$3.10B
Sector
TechnologyTechnology
52-Week High
$369.19$150.42
52-Week Low
$90.03$61.99
Enterprise Value
$5.11B$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Duolingo Inc

Duolingo trades at $131.94, down 3.83% amid mixed signals. The stock shows strong fundamentals with revenue growing from $369M in 2022 to $1.04B in 2025 and net income turning positive to $414M. Technical indicators show a bullish moving average trend but neutral oscillators, with key support at $129. Recent Q2 2026 earnings beat expectations with $0.66 EPS versus $0.604 expected, though Q3 revenue guidance disappointed investors.

The outlook remains cautiously optimistic with 30% analyst buy ratings but significant execution risk. Growth investments pressure near-term margins while user engagement strengthens. Key risks include monetization challenges and competitive threats in the edtech space. The consensus price target of $121 suggests limited upside from current levels.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.

The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX